Zenith Drugs Limited (NSE:ZENITHDRUG)

Market Cap	714.25M -44.5%
Revenue (ttm)	1.76B +32.3%
Net Income	39.43M -44.9%
EPS	2.30 -44.9%
Shares Out	17.15M
PE Ratio	18.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,600
Open	41.15
Previous Close	41.10
Day's Range	40.50 - 41.65
52-Week Range	33.30 - 78.95
Beta	1.53
Analysts	n/a
Price Target	n/a
Earnings Date	May 29, 2026

About Zenith Drugs

Zenith Drugs Limited, together with its subsidiaries, manufactures and trades in branded, generic, and OTC medicines. The company offers a range of pharmaceutical formulations, such as ORS powder, liquid orals, ointments, creams, gels, liquid externals, capsules, and tablets. Its products are indicated for allergology, general analytics, infections, genetics, endocrinology, and microbiology. The company operates in India, Costa Rica, Mauritius, Cambodia, Myanmar, Yemen, Sierra, Leone, Liberia, and Bhutan. Zenith Drugs Limited was incorporated i...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1956
• Employees: 182
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ZENITHDRUG

Financial Performance

In fiscal year 2026, Zenith Drugs's revenue was 1.76 billion, an increase of 32.25% compared to the previous year's 1.33 billion. Earnings were 39.43 million, a decrease of -44.94%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 17, 2026

Data Sources Report a data error